ACTUATE THERAPEUTICS INC. - COMMON STOCK

Actuate Therapeutics Announces Closing of $17.25 Million Public Offering of Common Stock, Including Full Exercise of Over-Allotment Option

11 Sep 2025 13:01:00 By Nasdaq GlobeNewswire

Actuate Therapeutics Announces Pricing of $15.0 Million Public Offering of Common Stock

10 Sep 2025 05:31:02 By Nasdaq GlobeNewswire

Actuate Therapeutics Announces Proposed Public Offering of Common Stock

09 Sep 2025 13:07:09 By Nasdaq GlobeNewswire

Actuate Therapeutics To Collaborate with Incyte Corporation and the University of Pittsburgh on Clinical Trial of Elraglusib in Combination with Retifanlimab and mFOLFIRINOX in Patients with Advanced Pancreatic Cancer

06 Aug 2025 05:45:00 By Nasdaq GlobeNewswire

Actuate Therapeutics Advances Clinical Program in Ewing Sarcoma After Positive Phase 1 Trial Demonstrates Complete and Partial Responses in Difficult-to-Treat Pediatric Sarcomas

17 Jul 2025 05:45:00 By Nasdaq GlobeNewswire

Actuate Therapeutics Highlights Significant and Sustained Survival Benefit in Key Metastatic Pancreatic Cancer Patient Populations in Phase 2 Elraglusib Trial

24 Jun 2025 06:15:00 By Nasdaq GlobeNewswire

Actuate Therapeutics Reports Positive Biomarker and Machine Learning Data from Phase 2 Elraglusib Trial in First-Line Treatment of Metastatic Pancreatic Cancer at ASCO

20 Jun 2025 05:45:00 By Nasdaq GlobeNewswire

Actuate Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes

16 Jun 2025 05:30:00 By Nasdaq GlobeNewswire

Actuate Therapeutics Shares Highlights from KOL Event on Positive Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic Pancreatic Cancer

02 Jun 2025 06:00:00 By Nasdaq GlobeNewswire

Actuate Therapeutics Presents Topline Elraglusib Phase 2 Data at ASCO 2025 Annual Meeting: Trial Meets Primary Endpoint of Median Overall Survival and Doubles 1-Year Survival in First-Line Treatment of Metastatic Pancreatic Cancer

31 May 2025 13:30:00 By Nasdaq GlobeNewswire

Actuate Therapeutics Announces Details for 2025 ASCO Annual Meeting Presentation on Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic Pancreatic Cancer

22 May 2025 14:05:00 By Nasdaq GlobeNewswire

Actuate Therapeutics to Host KOL Event on Topline Phase 2 Data of Elraglusib in Metastatic Pancreatic Ductal Adenocarcinoma During ASCO Annual Meeting

07 May 2025 05:00:01 By Nasdaq GlobeNewswire

Actuate Therapeutics Announces Statistically Significant Topline Results from Global Phase 2 Trial of Elraglusib in First-Line Treatment of Metastatic Pancreatic Cancer

06 May 2025 05:00:01 By Nasdaq GlobeNewswire

Actuate Therapeutics to Participate in Citizens Life Sciences Conference 2025

30 Apr 2025 05:00:00 By Nasdaq GlobeNewswire

Actuate to Present Elraglusib Phase 2 Topline Data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

23 Apr 2025 07:24:10 By Nasdaq GlobeNewswire

Actuate to Present Promising Data on Elraglusib in Advanced Salivary Gland Carcinoma at the AACR Annual Meeting 2025

17 Apr 2025 05:00:00 By Nasdaq GlobeNewswire

Actuate Announces Completion of Enrollment in a Phase 2 Trial of Elraglusib in Combination with FOLFIRINOX and Losartan in Patients with Previously Untreated Metastatic Pancreatic Cancer

25 Feb 2025 05:00:00 By Nasdaq GlobeNewswire

Actuate Therapeutics to Participate in Upcoming Investor Conferences in February

06 Feb 2025 05:00:00 By Nasdaq GlobeNewswire

Actuate Therapeutics Receives EMA Orphan Medicinal Product Designation for Elraglusib for the Treatment of Pancreatic Cancer

07 Jan 2025 05:00:01 By Nasdaq GlobeNewswire

Actuate Therapeutics Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer

17 Dec 2024 05:28:17 By Nasdaq GlobeNewswire